Bristol Myers Squibb vs Merck & Co.
Prices at close . Model readings .
Bristol Myers Squibb
$60.57−1.59%- Market value
- $124.05B
- P/E
- 13.0
- 1 year
- +44.3%
Merck & Co.
$140.93−0.63%- Market value
- $358.95B
- P/E
- 760.8
- 1 year
- +63.9%
Price change, with the S&P 500 as a benchmark
Percent change in each close since the start of the chosen range, for both companies and the S&P 500 (SPY). Daily closes over the last year, weekly before that and monthly before five years.
How the two compare
On the latest closes (28 Oct 2026), Merck & Co. is the larger company by market value ($358.95B against $124.05B). Over the past year Bristol Myers Squibb returned +44.3% and Merck & Co. +63.9%, while the S&P 500 returned +12.7%. The latest filed P/E is 13.0 for Bristol Myers Squibb and 760.8 for Merck & Co., and the operating margin 22.6% against -0.5%. Over the next 21 sessions the model expects +0.09% for Bristol Myers Squibb, with a 57% chance of a rise, and −0.34% for Merck & Co., with a 37% chance. Bristol Myers Squibb's long-run fair value is $67.39, a gap of +11.3% to its price; the long-run model view is positive. Merck & Co.'s long-run fair value is $131.14, a gap of −6.9% to its price; the long-run model view is neutral.
What the model expects
Expected returns and the chance of a rise from our forecasting models, and the long-run fair value against the price. Readings, not advice.
How the prices moved
Price change over each period, with the S&P 500 (SPY) for comparison.
What the market pays
Size and the multiples from the latest filed quarter. A P/E on losses reads n/m.
How much of revenue becomes profit
Margins and returns on capital from the latest filing; revenue, net income and earnings per share over the trailing twelve months.
How fast the business grew
Change against the same quarter a year earlier.
Balance sheet and quality scores
Leverage, liquidity and two published scores: Altman Z (below 1.8 the distress zone, above 3 the safe zone) and Piotroski F (0 to 9).
How the shares trade
Volatility, sensitivity to the market, the deepest fall, short interest and how closely the two move together.
Bristol Myers Squibb or Merck & Co.: common questions
Which is larger by market value, Bristol Myers Squibb or Merck & Co.?
Merck & Co., at $358.95B against $124.05B for Bristol Myers Squibb, on the latest closes (28 Oct 2026).
Which has the higher P/E ratio, Bristol Myers Squibb or Merck & Co.?
Merck & Co. has the higher latest filed P/E, 760.8; Bristol Myers Squibb's is 13.0. Filings: quarter to 30 Jun 2026 and 31 Dec 2023.
How did Bristol Myers Squibb and Merck & Co. move over the past year against the S&P 500?
Over the past year Bristol Myers Squibb returned +44.3% and Merck & Co. +63.9%, while the S&P 500 returned +12.7%. Prices at close 28 Oct 2026.
What does the model expect for Bristol Myers Squibb and Merck & Co. over the next month?
+0.09% for Bristol Myers Squibb with a 57% chance of a rise, and −0.34% for Merck & Co. with a 37% chance, over the next 21 sessions. Model readings 28 Oct 2026. These are model readings, not advice.
How do the operating margins of Bristol Myers Squibb and Merck & Co. compare?
The operating margin is 22.6% for Bristol Myers Squibb and -0.5% for Merck & Co., and the gross margin 71.3% against 73.2%. Filings: quarter to 30 Jun 2026 and 31 Dec 2023.
Do Bristol Myers Squibb and Merck & Co. shares move together?
Over the past year the correlation of their daily returns was 0.46 (loosely together); 1 means they always move together, 0 unrelated, −1 opposite. Prices at close 28 Oct 2026.
Model readings are research estimates, not investment advice. Prices: daily closes. Fundamentals: the latest SEC filings. Short interest: FINRA, settlement 30 Sep 2026. A dash means the figure is not in our data; it is never shown as zero. The model view follows a published rule: next month by the sign of the expected return, the long run positive at a fair value 10% or more above the price and negative at 10% or more below it.